Pathalys Pharma

Stories

Upacicalcet meets primary endpoint in two Phase 3 trials for dialysis patients

Developing upacicalcet for US approval; presented Phase 3 data at ASN Kidney Week 2026 and has not set an FDA filing date

Nearly all dialysis patients develop secondary hyperparathyroidism, a condition where parathyroid hormone rises out of control and raises the risk of bone fractures and heart disease. On October 23, Pathalys Pharma reported that its intravenous drug upacicalcet cut parathyroid hormone by at least 30% in 42% of treated patients, against 17% on placebo, in two identical Phase 3 trials.

Updated Nov 2